Portfolio Items • Bios Partners

Portfolio Companies

Advanced small molecules

Actuate (NASDAQ: ACTU) is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases.

Visit Their Site

Macrophage immunotherapy

BobcatBio is a clinical-stage immuno-oncology company developing an activated macrophage cell therapy for personalized treatment of both solid and liquid tumors through wholistic activation of the patient's own immune system.

Visit Their Site

Advanced small molecules

Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company focused on synaptic health and restoration in neurodegenerative disorders through a pipeline of disease modifying small molecule drug candidates.

Visit Their Site

Medical Devices

i-Lumen Scientific, Inc. is clinical-stage medical company developing a next-generation, non-invasive, transpalpebral microcurrent electrical stimulation device to treat patients with visual acuity loss due to retinal degeneration.

Visit Their Site

Engineered cell therapy

Immusoft Corporation is a clinical-stage biopharmaceutical company developing genetically modified B cell therapies to treat rare genetic diseases.

Visit Their Site

Engineered cell therapy

IN8bio (NASDAQ: INAB) is a clinical-stage immune-oncology company focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer.

Visit Their Site

AI Drug Development

Lantern Pharma (NASDAQ: LTRN) is a clinical stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. Lantern leverages advances in machine learning, genomics and artificial intelligence to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics.

Visit Their Site

Advanced small molecules

ONL Therapeutics is a clinical-stage company with a novel approach to preserving sight and halting vision loss associated with a range of retinal disease. The company is advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the Fas pathway.

Visit Their Site

Gene therapy

Opus Genetics (NASDAQ: IRD) is a clinical-stage company developing ocular AAV gene therapies to address a large pipeline of rare genetic blinding conditions that have no current treatment options.

Visit Their Site

Advanced small molecules

Rein Therapeutics (NASDAQ: RNTX) is a clinical-stage biopharmaceutical company developing disease-modifying treatments for fibrotic and pulmonary diseases.

Visit Their Site

Advanced small molecules

Renibus Therapeutics is a clinical-stage biopharmaceutical company developing treatments to protect against organ damage associated with cardio, renal, and metabolic diseases.

Visit Their Site

Recombinant proteins/antibodies

Stream Biomedical is a preclinical biotechnology company focused on leveraging its engineered perlecan domain V to develop first-in-class treatments for serious neurogenerative disorders such as stroke.

Visit Their Site

Recombinant proteins/antibodies

Trefoil Therapeutics is a clinical-stage biotechnology company focused on developing engineered biologics for the treatment of serious corneal diseases.

Visit Their Site

Acquired/Exited Portfolio Companies

Advanced small molecules

Encore Vision is a clinical-stage subsidiary of Novartis that is developing novel small molecule therapies for the topical treatment of presbyopia, a condition of worsening vision due to aging.

Visit Their Site

Engineered cell therapy

Taysha Gene Therapies (NASDAQ: TSHA) is a clinical staged company focused on the treatment of monogenic CNS disease. Taysha is advancing an extensive AAV gene therapy pipeline, with lead candidates in GM2 gangliosidosis, Rett syndrome, and CLN1.

Visit Their Site